Pages:
- A new name for a new era
- About GBMA
- Advocacy
- Biosimilars
- Extended Strategic Agreement
- GBMA Code of Practice
- GBMA Education
- Generic Medicines Facts
- Key Industry Facts
- Links
- Site Map
- Strategic agreement recognises the important role of generic and biosimilar medicines in delivering affordable healthcare
- Test Home
- Home
Categories:
Authors:
Monthly:
- July 2019
- May 2019
- April 2019
- March 2019
- September 2018
- August 2018
- June 2018
- April 2018
- February 2018
- October 2017
- September 2017
- August 2017
- June 2017
- May 2017
- April 2017
- March 2017
- December 2016
- November 2016
- September 2016
- July 2016
- May 2016
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- May 2015
- March 2015
- February 2015
- December 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- March 2014
- February 2014
- June 2013
- February 2013
Recent Posts:
- As focus grows for biosimilars, GBMA welcomes its newest member Celltrion
- GBMA welcomes Minister Hunt’s return to the Health portfolio
- Budget 2019-20 – Budget spending on health and new medicines a welcome investment in the health of Australians
- Health Minister Announces Details of 2019 Biosimilar Week
- Peak body for Generic and Biosimilar medicines welcomes legislation to inform patients about medicine shortages
- GBMA Education Commences 2018-2019 Grant Activities
- GBMA appoints project manager to lead the delivery of its Biosimilar Education Grant initiatives
- IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly
- Biosimilar Educational Grant awarded to GBMA Education
- GBMA announcement of new Chair
- GBMA announces the appointment of new CEO
- Belinda Wood to leave GBMA
- GBMA welcomes newest member – Juno Pharmaceuticals
- Pharmaceutical IP reform welcomed however complex issues remain
- Report lists all new generic and biosimilar medicines in 2016
- Budget 2017: GBMA welcomes initiatives to increase the use of affordable medicines
- Biosimilar naming – why changing the way we name biosimilar medicines won’t fix the problem some think we have.
- Misleading Grattan Institute Report risks ongoing supply of everyday medicines to Australian families
- Another infliximab biosimilar highlights need for uptake
- Prominent UK specialist to share biosimilar experience – health system savings and expanded patient access to the latest treatments
- GBMA welcomes Health Minister’s plans to streamline medicines regulation
- Biosimilar etanercept approval great news for Australian patients
- Budget 2016: Significant PBS savings and regulatory improvements confirmed
- Longer patents do not incentivise innovation or attract R&D to Australia
- Government and GBMA agree policy priorities for PBS and industry viability
- TPP finalised with no extension to data exclusivity for medicines: GBMA
- May Conference 2015
- Biosimilar infliximab approval great news for Australian patients
- GBMA welcomes PBS listing of biosimilar infliximab
- Allan Tillack Chair of GBMA
- A new name for a new era
- ‘A stronger, more focussed organisation’ Mark Crotty steps down as GMiA Chair
- GMiA welcomes new member – Amneal Pharmaceuticals
- Strategic agreement recognises the important role of generic and biosimilar medicines in delivering affordable healthcare
- GMiA welcomes the PBAC consideration of “a” flagging biosimilars, and the PBS listing of the first biosimilar insulin.
- GMiA launches a Guide to Biosimilars
- Biosimilar infliximab launch in EU is a great sign for Australian patients: GMiA
- GMiA welcomes new Minister for Health, Sussan Ley
- GMiA announces Belinda Wood as new CEO
- GMiA welcomes efficient patient access to affordable medicines
- Generic Medicines Manufacturing keeps Australia healthy – A fair go will keep it viable –
- Kate Lynch to step down as CEO of GMiA
- GMiA welcomes new member – Sandoz
- Congratulations to Prof Jane Halton on her new appointment
- Recognition of ongoing generic medicines savings
- The Commission’s Nuclear Option to attack the PBS is Madness
- GMiA welcomes the release of the Pharmaceutical Patent Review
- GMiA calls on government to think before irreversible damage occurs to the generic medicines industry
- Setting the record straight: PBS expenditure is in decline
- Media Enquiries
- Members Login
- Members information